Renaissance Technologies
FBLG icon

Renaissance Technologies’s FibroBiologics FBLG Stock Holding History

Renaissance Technologies’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Buy
15,997
+4,417
+38% +$26.3K ﹤0.01% 3166
2025
Q4 		$52.1K Buy
11,580
+8,590
+287% +$60.5K ﹤0.01% 3088
2025
Q3 		$32.7K Buy
+2,990
New +$35.8K ﹤0.01% 3394

Other funds holding FBLG

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FEG
Fund Evaluation Group Cincinnati, Ohio $3.25B AUM 14.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Renaissance Technologies's FBLG Position: Q1 2026 in Review

Renaissance Technologies increased its FibroBiologics (FBLG) stake by 38% in Q1 2026, buying an estimated $26.3K and bringing the position to 15,997 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3166.

Renaissance Technologies first reported a position in FBLG in Q3 2025 and has held it in 3 quarters since. The position peaked at $52.1K in Q4 2025. 17 funds tracked by Wall St. Rank hold FBLG as of Q1 2026.

  • Renaissance Technologies held 15,997 shares of FibroBiologics worth $21.1K as of Q1 2026.
  • Renaissance Technologies bought 4,417 FibroBiologics shares in Q1 2026, an estimated $26.3K.
  • FibroBiologics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3166 holding.
  • Renaissance Technologies first reported a position in FibroBiologics in Q3 2025 and has held it in 3 quarters since.
  • Renaissance Technologies's FibroBiologics position peaked at $52.1K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held FibroBiologics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.